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Identifying  links  between  specific  infectious 
agents  and  cancer  greatly  impacts  the  prevention  of 
these  cancers.  Furthermore,  understanding  the  role  of 
cellular  factors  that  mediate  the  effect  of  infectious 
agents may reveal additional cancer control strategies. A 
potential association between cancers and infection with 
mycoplasma,  the  smallest  self-replicating  prokaryote, 
has been suspected since the 1960’s (reviewed in [1]). 
However, early evidence was weakened by the difficult 
culture conditions demanded by these fastidious microbes. 
More recent studies have used techniques such as PCR, 
immunohistochemistry,  and  serum  antibody  status. 
These  improved  detection  methods  have  shown  that 
healthy individuals are often colonized without obvious 
clinical effects [2, 3]. Later studies continue to support an 
association between various species of mycoplasma and 
human cancers (e.g., [4-8]). 
This study by Barykova et al. [7] is the latest of 
several that indicate a strong link between mycoplasma 
species  and  prostate  cancer  [8,  9].  Barykova  et al. 
used  real  time  PCR  to  demonstrate  that  Mycoplasma 
hominis levels in biopsies from patients with high-grade 
prostatic  intraepithelial  neoplasia  (HGPIN)  or  prostate 
cancer  (PCa)  were  triple  that  of  patients  with  benign 
prostatic  hyperplasia  (BPH,  p  =  0.002).  Other  species 
commonly found in the urogenital tract, M. genitalium 
and Ureaplasma urealitycum, were detected at a lower 
frequency.  Most  significantly,  no  mycoplasma  species 
were detected in control samples from lesion free men. 
Culturing confirmed the presence of M. hominis and U. 
urealitycum  in  prostate  tissue  (M. genitalium was  not 
cultured). Finally, antibodies against M. hominis protein 
p120  were  detected  in  the  serum  of  HGPIN  or  PCa 
patients  twice  as  frequently  as  in  patients  with  BPH. 
The  Barykova  et  al.  study  is  corroborated  by  another 
study that determined that PCa patients were more likely 
to  bear  antibodies  against  U. urealitycum  [8].  Finally, 
M. genitalium and M. hyorhinis  infection  caused  the 
malignant  transformation  of  benign  human  prostate 
(BPH-1) cells in vitro [9]. 
Laboratory  studies  strongly  support  the  ability 
of  mycoplasma  to  cause  or  promote  oncogenic 
transformation.  Several  different  species  have  been 
proven to transform rodent and human lines of diverse 
lineages  in vitro  [9-12].  Many  plausible  mechanisms 
would  explain  this  pro-cancer  effect:  the  induction  of 
genetic instability [11, 13, 14], alterations in metabolism 
[2, 3, 15], and dramatic changes in the expression of many 
genes. Specific genes include known tumor suppressors 
and oncogenes [16, 17] and many potent cell signals, such 
as pro-inflammatory cytokines and other growth factors 
[15, 18-21]. Infected tumor cells or adjacent infected cells 
may synthesize cytokines and growth factors that promote 
the growth of nascent tumor cells. Increased growth rate, 
along with increased mutation rate, would facilitate the 
transformation of infected cells. 
We were the first to demonstrate that mycoplasma 
oncogenically  transformed  human  lung  cells  [12].  We 
also  discovered  that  mycoplasma  species  rank  among 
the best known inducers of bone morphogenetic protein 
(BMP) 2 [12]. This is particularly relevant to lung cancer, 
because BMP2 RNA and protein levels are abnormally 
elevated  in  lung  tumors  [22-24].  BMP2  activates  pro-
oncogenic pathways (e.g., PI3K/mTOR; Smad1,5/Id-1) 
and promotes lung tumor growth in mice [25-27]. The 
BMP2 antagonist, noggin, reduces mixed metastatic lung 
cancer lesions in bone [28] and the growth of transformed 
lung cells in monolayer and in soft agar [12]. Finally, high 
BMP2 levels are associated with poor patient survival 
[29]. 
At  the  least,  mycoplasma  infection  is  a  potential 
biomarker for prostate malignancy. At best, the prostate 
cancer/mycoplasma  link  suggests  that  more  aggressive 
antibiotic  treatment  of  mycoplasma-infected  men  may 
be beneficial. Although smoking is the most important 
cause  of  lung  cancer,  other  factors  contribute  to  the 
development of lung cancer [30]. Proof that mycoplasma Oncotarget 2011; 2:  271 - 273 272 www.impactjournals.com/oncotarget
also influences lung cancer would facilitate the prevention 
and/or treatment of lung cancer. In addition, understanding 
the  signals  such  as  BMP2  that  mediate  the  effect  of 
mycoplasma may reveal other therapeutic options for a 
disease that is the leading cause of cancer deaths in the 
United States. 
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